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ABSTRACT 
The transforming growth factor beta (TGF) superfamily includes TGF, activins, inhibins and bone 
morphogenetic proteins (BMPs). These extracellular ligands have essential roles in normal tissue 
homeostasis by co-ordinately regulating cell proliferation, differentiation, and migration. Aberrant 
signalling of superfamily members, however, is associated with fibrosis as well as tumourigenesis, 
cancer progression, metastasis and drug-resistance mechanisms in a variety of cancer sub-types. Given 
their involvement in human disease, the identification of novel selective inhibitors of TGF superfamily 
receptors is an attractive therapeutic approach. Seven mammalian type 1 receptors have been identified 
that have context specific roles depending on the ligand and the complex formation with the type 2 
receptor. Here we characterise the biological effects of two TGFBR1 kinase inhibitors designed to target 
TGF signalling. AZ12601011 (structure previously undisclosed) and AZ12799734 (IC50s, 18nM and 
47nM respectively) were more effective inhibitors of TGF-induced reporter activity than SB-431542 
(IC50, 84nM) and LY2157299 (galunisertib) (IC50, 380nM). AZ12601011 inhibited phosphorylation 
of SMAD2 via the type 1 receptors ALK4, TGFBR1 and ALK7. AZ12799734, however, is a pan 
TGF/BMP inhibitor, inhibiting receptor-mediated phosphorylation of SMAD1 by ALK1, BMPR1A and 
BMPR1B and phosphorylation of SMAD2 by ALK4, TGFBR1 and ALK7. AZ12601011 was highly 
effective at inhibiting basal and TGF-induced migration of HaCaT keratinocytes and furthermore 
inhibited tumour growth and metastasis to the lungs in a 4T1 syngeneic orthotopic mammary tumour 
model. These inhibitors provide new reagents for investigating in vitro and in vivo pathogenic processes 
and the contribution of TGF and BMP regulated signalling pathways to disease states.      
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INTRODUCTION  
The Transforming Growth Factor- cytokine superfamily, including TGF, activin, inhibins, nodal and 
bone morphogenetic proteins (BMPs), regulate developmental and cellular biology to control and 
maintain tissue homeostasis. In different contexts, the interaction of the dimeric ligands with their 
cognate receptors activate intracellular signalling pathways to control cell death, survival, adhesion, 
differentiation, movement and deposition of components of the extracellular matrix (Shi and Massague, 
2003). In human disease the expression of, or cellular responses to, these factors may become 
deregulated. The resulting aberrant signalling can contribute to many disease pathologies including 
cancer, fibrosis, atherosclerosis and scarring (Blobe et al., 2000). TGF, for example, can switch from 
tumour suppressor to tumour promoter functions depending on epigenetic/genetic changes occurring in 
the tumour cell (Inman, 2011). Given their extensive role in human disease, the ligands, their receptors 
and their downstream effectors are considered attractive therapeutic targets (Akhurst and Hata, 2012).    
Cytokine signalling is initiated by the formation of heterotetrameric complexes of six polypeptides 
comprising dimeric ligands, two constitutively active type 2 receptors and two type 1 receptors. Upon 
complex formation, the serine/threonine kinase type 1 receptors are phosphorylated and activated by 
the type 2 receptors which initiates a canonical signalling cascade involving the recruitment, 
phosphorylation and activation of receptor-regulated SMADs. The phosphorylated SMADs bind to 
SMAD4 and the complexes accumulate in the cell nucleus where they both positively and negatively 
regulate gene expression. In addition, a number of SMAD-independent non-canonical signalling 
pathways (e.g. mitogen-activated protein kinases, Rho GTPases and phosphoinostide-3-kinases) are 
also activated which impact on gene regulation and cellular responses (Zhang, 2009). Five type 2 and 
seven type 1 receptors have been identified in mammalian cells. Their specificity for ligand and receptor 
complex formation determines biological outcome (Schmierer and Hill, 2007). For instance, TGF 
interacts primarily with TGFBR2 and the ubiquitous type 1 receptor TGFBR1 to regulate cytostasis, 
apoptosis and epithelial to mesenchymal transition (EMT), but both TGF and GDF2 (BMP9) may 
bind to the endothelial cell restricted type 1 receptor ACVRL1 to regulate angiogenesis. In some 
circumstances, TGFβ may also signal via TGFBR1 and ALK2 to induce SMAD1/5 phosphorylation 
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and a subset of TGFβ-inducible genes involved in EMT (Ramachandran et al., 2018). BMPs, 
meanwhile, bind selectively to BMPR2 and the type 1 receptors activin A receptor type 1L (ALK1), 
activin A receptor type 1 (ALK2), bone morphogenetic protein receptor type 1A (BMPR1A), and bone 
morphogenetic protein receptor type 1B (BMPR1B) to regulate embryogenesis and bone formation 
(Wang et al., 2014). TGF, Activin and Nodal signal via TGFBR1, ALK4 and ALK7, respectively, 
predominantly to phosphorylate and activate SMAD2 and SMAD3 while BMPs induce phosphorylation 
of SMAD1, SMAD5 and SMAD8.  
Given the role of TGF in pathological states, there have been numerous therapeutic approaches taken 
to blockade signalling with some progressing through preclinical evaluation to clinical trial (Akhurst 
and Hata, 2012; Lahn et al., 2005). Some selective small molecule inhibitors (SMI) of the TGFBR1 
kinase are well characterised (e.g. SB-431542) (Inman et al., 2002; Vogt et al., 2011) and have been 
used extensively in preclinical models to interrogate TGF-regulated biological pathways. SMIs of 
TGFBR1 have shown therapeutic promise in models of fibrosis (Gellibert et al., 2006; Park et al., 2015a; 
Park et al., 2015b), and two TGFBR1 inhibitors are currently in clinical trials, vactosertib (TEW-7197) 
and galunisertib (LY2157299). The results of the first in human trials with vactosertib 
(ClinicalTrials.gov Identifier: NCT02160106) are not yet reported. Galunisertib, however, has 
progressed despite some initial toxicity concerns, and is now considered safe enough when administered 
with careful dosing schedules (Fujiwara et al., 2015; Herbertz et al., 2015; Kovacs et al., 2015), to allow 
further clinical development in cancer patients with unmet need. TGFBR1 inhibitors therefore remain 
attractive leads for drug development.  
AZ12601011 (structure previously undisclosed) and AZ12799734 (Anderton et al., 2011; Goldberg et 
al., 2009) are two selective TGFBR1 inhibitors. AZ12601011 and AZ12799734 inhibit TGFBR1 kinase 
activity (competition binding) with Kd values of 2.9nM and 740nM, respectively. Both compounds 
have some inhibitory activity against the related receptors ALK4 and BMPR1B, but are only weakly 
active against ALK1, ALK2 and BMPR1A in in vitro kinase assays (Anderton et al., 2011). Here, we 
characterise their specificity and in vitro and in vivo biological activity in a variety of cell-based 
biochemical and functional assays, in comparison with other well studied and clinically relevant 
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TGFBR1 SMIs. We show that AZ12601011 is a selective inhibitor of ALK4, ALK7 and TGFBR1. 
Importantly, AZ12601011 inhibited TGF-induced epithelial cell migration at 10-fold lower 
concentrations than galunisertib and was effective in an in vivo tumour model system. Additionally, we 
identify AZ12799734 as a pan BMP/TGF inhibitor providing a novel spectrum of single agent 
inhibitory activity useful for analytical evaluation of TGF superfamily regulated processes.   
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MATERIALS AND METHODS 
 
Synthetic procedures for AZ12799734 have been described previously (Compound 19, 
(Goldberg et al., 2009)  
Synthetic procedures for AZ12601011: 
2‐Pyridin‐2‐yl‐1,5,6,7‐tetrahydrocyclopenta[e]pyrimidin‐4‐one2‐Amidinopyridine hydrochloride (7.88 
g,  50  mmol)  and  K2CO3  (6.91  g,  50  mmol)  were  added  to  methyl  2‐oxocyclopentanecarboxylate 
(commercially sourced) (6.21 mL, 50 mmol) in ethanol (100 mL). The mixture was heated to reflux for 
5 hours. While the mixture was still hot, it was acidified by the addition of 2 M aq. HCl (20 mL), and 
water (30 mL). The mixture was allowed to cool to room temperature overnight and was then was 
partially  concentrated  in  vacuo.  The  resulting  precipitate was  collected  by  filtration, washed with 
water  and  diethyl  ether  and  dried  in  vacuo  to  give  the  desired  product.  Additional  product  was 
obtained by concentrating the filtrate in vacuo and purifying the resulting residue by recrystallisation 
from ethanol/water. The  two batches were combined  to afford  the  title  compound  (3.63 g, 34%). 
1H NMR (DMSO‐d6): 2.04 (2H, quintet), 2.71 (2H, t), 2.88 (2H, t), 7.63 (1H, dd), 8.04 (1H, t), 8.30 (1H, 
d), 8.73 (1H, d), NH missing; m/z MH+ 214. 
 
O
N
N N
 
4‐Chloro‐2‐pyridin‐2‐yl‐6,7‐dihydro‐5H‐cyclopenta[d]pyrimidine  POCl3  (4.72  mL,  50.7  mmol)  was 
added  to  2‐pyridin‐2‐yl‐1,5,6,7‐tetrahydro‐cyclopenta[e]pyrimidin‐4‐one  (2.7  g,  12.7  mmol).  The 
mixture was heated at reflux for 1 hour and was then cooled to room temperature. The mixture was 
concentrated in vacuo and extracted with CH2Cl2/CH3OH. The organic layer was washed sequentially 
with 5% aq. NaOH and sat. brine, then dried (MgSO4), and concentrated in vacuo to afford the title 
compound (2.60 g, 89%) as a solid. 1H NMR (DMSO‐d6) 2.20 (2H, qn), 3.06 (2H, t), 3.16 (2H, t), 7.79 
(1H, t), 8.27 (1H, dt), 8.53 (1H, d), 8.82 (1H, d); m/z MH+ 232. 
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1-(2-Pyridin-2-yl-6,7-dihydro-5H-cyclopenta[e]pyrimidin-4-yl)pyrrolo[3,2-c]pyridine (AZ12601011) 
5‐Azaindole (1.32 g, 11.1 mmol), Cs2CO3 (6.05 g, 18.6 mmol), palladium(II) acetate (0.125 g, 0.56 mmol) 
and  (R)‐(‐)‐1‐[(S)‐2‐(dicylohexylphosphino)ferrocenyl]ethyldi‐tert‐butylphosphine  (0.644  g,  1.11 
mmol) were added to 4‐chloro‐2‐(pyridin‐2‐yl)‐6,7‐dihydro‐5H‐cyclopenta[d]pyrimidine (2.15 g, 9.28 
mmol) in 1,4‐dioxane (46.4 mL) and the mixture was heated at reflux for 3 hours. The mixture was 
allowed to cool to room temperature then concentrated  in vacuo  to give a brown gum which was 
partitioned  between  CH2Cl2/water.  The  organic  layer  was  isolated  and  dried  (MgSO4)  and 
concentrated  in vacuo. The resulting crude mixture was purified by  flash column chromatography, 
eluting with 0‐5% CH3OH  in CH2Cl2,  to afford  the  title compound  (1.44 g, 50%) as a  solid.  1H NMR 
(DMSO‐d6) 2.21 (2H, quintet), 3.15 (2H, t), 3.28‐3.34 (2H, m), 7.01 (1H, dd), 7.58 (1H, dq), 8.01‐8.06 
(2H, m), 8.45 (1H, d), 8.46 (1H, dt), 8.65 (1H, dt), 8.84 (1H, dq), 9.00 (1H, d); m/z MH+ 314. 
 
N
N
N
N N
AZ12601011
 
 
Plasmids 
Plasmids expressing SMAD1 and SMAD2 and constitutively active ALK1, ALK2, BMPR1A, ALK4, 
TGFBR1, BMPR1B and ALK7 used in transient transfections have been described previously (Inman 
et al., 2002).     
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Cell culture  
HaCaT, C2C12, T47D, VU-SCC-040, NIH3T3, NIH 3T3-CAGA12-luc, C2C12-BRE-luc and murine 
4T1 [4T1-Luc (RRID:CVCL_J239)] cell lines were maintained in DMEM supplemented with 10% 
FBS and glutamine. Media for NIH 3T3-CAGA12-luc cells was also supplemented with 400mg/mL 
G418, media for C2C12-BRE-luc was supplemented with 700mg/mL G418. All cells lines were 
confirmed negative for mycoplasma contamination by the Institute’s mycoplasma testing service. Cells 
were exogenously stimulated with TGF1 (Peprotec) resuspended in 1mg/mL BSA/4mM HCl. 
Inhibitors were diluted in DMSO at 1000-2000x final concentration required. Appropriate BSA/HCl 
and DMSO vehicle controls were used throughout. Osmotic shock was induced by treatment of cells 
for 20 minutes with 0.7M NaCl prepared in DMEM and was used to induce p38 MAPK phosphorylation 
(Davis, 2000).  Epidermal growth factor (EGF) treatment was carried out by exogenous addition of 
30ng/mL EGF for 5 minutes. The MEK1/2 inhibitor U0126 (Tocris) was used at a concentration of 
25M.  
C2C12-BRE luciferase and NIH3T3-CAGA12 luciferase reporter bioassays 
The C2C12-BRE-luciferase (Herrera and Inman, 2009) and NIH3T3-CAGA12-luciferase stable cell 
lines (Spender et al., 2016) used in the bioassays have been described previously. Cells were seeded 
overnight at 1x104/well in 96-well plates. Cells were then pre-treated for 20 minutes with a titration of 
SB-431542 (Inman et al., 2002) (Tocris), SB-525334 (Sigma), AZ12601011 (Anderton et al., 2011), 
AZ12799734 (AstraZenica) or LY2157299 (galunisertib) (Selleck) followed by stimulation with 
exogenous TGF (1ng/mL) or BMPs. Cell lysates were analysed by the Luciferase Assay system 
(Promega) as recommended by the manufacturer. The mean percent activity (± S.D) of the reporter in 
the presence of the inhibitors relative to maximal activation induced by TGF or BMPs (100%) is 
shown.  
Dose response IC50 (Dm) calculation and proliferation curve analysis 
IC50 values were determined by curve fitting using either non-linear regression (Graphpad Prism 7) or 
CalcuSyn Version 2.11 software (Biosoft, UK) which reports median-effect plots, the median dose 
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(Dm, IC50) and the correlation coefficient (r). 95% confidence intervals of IC50 were determined using 
Graphpad Prism 7 software. Statistical analysis of cell proliferation curves was carried out by pairwise 
comparison between two or more groups of growth curves using the compareGrowthCurves function 
from statmod (R project). The number of permutations nsim=10000, p values given were adjusted for 
multiple testing.  
Western blotting and antibodies. 
Cell lysates were analysed by SDS-PAGE using the following antibodies: phospho-SMAD2 
(Ser465/467) (rabbit polyclonal, #3101, Cell Signalling Technology [CST]), phospho-SMAD1 (rabbit 
polyclonal, #9511, CST, phospho-ERK (rabbit polyclonal phospho  p44/42  (Thr202/Tyr204) MAPK, 
#9101, CST), phospho-p38 (Thr180/Tyr182) (rabbit polyclonal, #9211, CST), SMAD1 (rabbit 
polyclonal #38-5400, Zymed), SMAD2 (mouse monoclonal, C16D3, CST), SMAD2/3 (mouse 
monoclonal, Clone 18, BD transduction Laboratories). Secondary HRP-conjugated antibodies (Dako) 
and enhanced chemiluminescence (GE Healthcare) was used to detect bound antibody. LI-COR infrared 
imaging was carried out using a LI-COR Odyssey system following western blotting using rabbit 
monoclonal anti-phospho-SMAD2 (Ser465/467) (138D4), #3108, CST and mouse monoclonal pan-
SMAD2 antibody (L16D3) #3103 CST. Secondary antibodies were IRDye® 680RD Donkey 
(polyclonal) anti-Rabbit IgG (H+L), #925-68073, LI-COR and IRDye® 800CW goat anti-mouse IgG 
(H + L), #926-32210, LI-COR. Analysis of signal intensities was carried out using LI-COR Image 
Studio v4.0.21 software. Signal  was  normalised  to  pan‐SMAD2  levels  measured  on  channel  800 
according to the manufacturer’s signal protein normalisation strategy (SPS).  
 
Wound healing assay, IncuCyte Zoom and data analysis 
An IncuCyte Zoom live cell imaging microscope (Essen Biosciences) with 10x objective and data 
management software was used to monitor cell migration in wound healing assays. HaCaT cells were 
seeded overnight in 100mL growth media at 15000 cells/well in 96-well ImageLock plates (Essen 
Bioscience). Cells were washed twice in PBS and serum starved for 24 hours in DMEM supplemented 
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with 0.2% FBS to minimise proliferation which would interfere with migration assays. Uniform wounds 
were then generated using a Woundmaker, the cells washed twice in PBS, and then pre-treated for 20 
minutes with titrations of LY2157299 (galunisertib), SB-431542, AZ12601011 or AZ12799734 in 
DMEM/0.2% FBS. Cells were then treated with BSA/HCL as a carrier control or TGF (5ng/mL). 
Closure of the wound was monitored by IncuCyte Zoom imaging over 4 days. Data presented is the 
mean ± S.E.M of a minimum of three replicate wells taken from a representative experiment. The mean 
± SEM relative wound density were determined according to software processing definitions as 
recommended by the manufacturer.   
In vivo 4T1 syngeneic orthotopic mammary fat-pad model for efficacy and PK/PD 
The 4T1 cell line was maintained in RPMI 1640 (Invitrogen) supplemented with 10% FCS (Sigma 
Aldrich) and M1 (Egg Technologies) with 1% glutamine (Invitrogen) in 7.5% CO2 at 37°C and were 
detached using 0.05% trypsin (Invitrogen). Cells were implanted in to mammary fat pad 4 in 30μL 
PBS/A at 1x104 per mouse.  Female BALB/c mice (Charles River) at greater than 18g had tumour sizes 
monitored three times weekly by bilateral caliper measurements. Tumour volume was calculated at 
each measure with dosing from the day following implant. Controls received vehicle only (0.5% 
Methocel E4 Premium / 0.1% Polysorbate 80) by oral gavage twice daily for the duration of the study. 
The treatment group received AZ12601011 50mg/kg twice daily in 0.5% Methocel / 0.1% Polysorbate. 
Samples for PK and PD analysis were sampled at 1 and 6h post final AM dose on Day 25. Additionally, 
lung samples were taken to assess the number of lung metastases.  Following formalin fixation each 
lobe was sectioned, creating five serial sections per lobe, 200μm apart. The sections were then stained 
with haematoxylin and eosin stain and the number of metastases counted using light microscopy. This 
study was run in the UK in accordance with UK Home Office legislation, the Animal Scientific 
Procedures Act 1986 (ASPA) and with AstraZeneca Global Bioethics policy. Experimental details are 
outlined in Home Office Project Licence 40/2934. Additional dosing was undertaken for PK profile 
analysis for AZ12601011 and AZ12799734 at 50mg/kg per oral dose in male nude mice in vehicle as 
detailed above. Statistical analysis was carried out using SPSS software (IBM).  
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In vivo pharmacokinetic analysis 
Each plasma sample (25 l) was prepared using an appropriate dilution factor and compared against 
an 11 point standard calibration curve (1‐10000 nM) prepared in DMSO and spiked into blank plasma. 
Acetonitrile (100 l) was added with the internal standard, followed by centrifugation at 3000 rpm for 
10 minutes. Supernatant (50 l) was then diluted in 300 l water and analyzed via UPLC‐MS/MS. The 
Mass Spectrometer and UPLC parameters are detailed below along with the optimisation parameters. 
Mass Specrometer and UPLC system parameters 
Mass Spec  Waters Ultima Pt     
HPLC system  Agilent 1100 HPLC   
Column   Waters x‐bridge C18 50 x 2.1, 3.5u    
Solvent A  95% Water, 5% MeOH + 10mM Ammonium Acetate      
Solvent B  95% MeOH, 5% Water + 10mM Ammonium Acetate       
Gradient  Time (min)  % A   %B
   0  95  5 
   3 
3.8 
3.81 
5 
5 
95 
95 
95 
5 
   4  95  5 
Flow  0.75 ml/min       
Run time  4 min, use a divert valve for initial 0.5 minutes  
 
Optimization parameters for mass spectrometry analysis 
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In vivo pharmacodynamic analysis of phospho-SMAD2 using ELISA 
Mouse total SMAD 2/3 mAB (BD Biosciences Cat 610843l) at 1.25μg/ml in PBS/A was used to coat 
Greiner black high-bind 96-well plates with incubation for 1hour at room temperature then inverted and 
blotted.  Blocking buffer with 3% BSA (Sigma A-3912) was added and the incubation/blotting process 
repeated.  4T1 tumour lysate was prepared at 100μg/well in AP lysis buffer containing fresh protease/ 
phosphatase inhibitors and then added to the wells for an overnight incubation at 4°C.  Following this 
incubation all wells were washed with TBS/T. A plate was incubated with primary antibody (Rabbit 
Upstate phospho-SMAD2, #05-953) and a second plate was incubated with primary antibody, Rabbit 
CST Total SMAD 2/3 (CST 3102).  Blocking buffer was used for the antibodies and the plates were 
incubated for 2hours at RT followed by washing with TBS/T. Anti-rabbit HRP conjugate (CST 7074) 
was added to the plates and incubated for 1hour followed by a further wash.  They were developed with 
Quantablu using the manufacturer’s recommended protocol and read on a Tecan SpectroFluor using 
excitation 340nm / 465nm emission.   
Compound 
Ionization 
mode  Polarity 
Parent 
ion 
Daughter 
ion 
Cone 
voltage (v) 
Collison 
Energy 
AZ12601011  ESI  Positive  314.2076  78.0667  80  46 
AZ12799734  ESI  Positive  371.15  290.21  50  34 
AZ10024306 
(ISTD)  ESI  Positive  408.253  174.189   80   22 
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RESULTS   
AZ12601011 and AZ12799734 inhibit ligand activated SMAD3/4 transcription.  
NIH 3T3 cells stably expressing a TGFβ inducible CAGA12-luciferase reporter construct were used to 
determine the effect of AZ12601011 and AZ12799734 (compound structures are shown in Fig.1A) on 
TGF-induced transcription in comparison with the previously characterised TGFBR1 inhibitors SB-
431542, SB-525334 and LY2157299 (galunisertib). The 12 tandem copies of the SMAD binding 
element CAGA (Dennler et al., 1998) regulate luciferase reporter gene activity in response to TGF 
receptor regulated SMAD3 and SMAD4 binding. Luciferase activity in cell lysates increased in 
response to TGF1 addition and was inhibited by all compounds tested (Fig 1B). The IC50s, determined 
by curve fitting from dose response curves (Fig. 1C) of AZ12601011 (18 ± 6nM) and AZ12799734 (47 
± 7nM), were lower than those of the other inhibitors and were approximately 10-fold lower than the 
IC50 of galunisertib (384 ± 170nM) approved for use in clinical trials (Figs 1C and 1D). Phosphorylation 
of SMAD2 induced by exogenous TGF addition, detected using a polyconal rabbit anti-
phosphorylated SMAD2 (ser465/467) antibody, was completely inhibited by the most active inhibitor 
AZ12601011 in four cell lines at concentrations between 300nM and 1M (Fig. 2A). The inhibition of 
SMAD2 phosphorylation in TGFβ treated HaCaT relative to pan-SMAD2 levels was quantified by LI-
COR infrared imaging using a second monoclonal rabbit anti-phosphorylated SMAD2 (ser465/467) 
(138D4) antibody (Fig. 2B-2D). Representative blots are shown in Fig. 2B, and combined raw intensity 
traces from channel 700 and 800 scans of lane 2 (control + TGFβ) measuring phospho-SMAD2 and 
pan-SMAD2, respectively are shown in Fig. 2C. Normalised phospho-SMAD2 levels relative to un-
induced levels (lane1) are shown in Fig. 2D, these returned to baseline in the presence of 0.3µM 
AZ12601011 and indicate similar levels of inhibition as those seen in Fig 2A.  
 
Stability and specificity of AZ12601011 and AZ12799734  
We next tested the suitability, stability and specificity of AZ12601011 and AZ12799734 as reagents for 
studying TGFβ family signalling in cell based assays. Neither AZ12601011 nor AZ12799734 showed 
any reduction in their ability to block CAGA12-luciferase reporter activity following up to six rounds of 
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freeze-thawing when used at concentrations selected to inhibit CAGA12 activity by approximately 50% 
(20nM and 60nM, respectively) (Fig. 3A). All four inhibitors tested maintained activity when incubated 
in tissue culture medium for up to 10 days (Fig. 3B) and effectively maintained efficacy in in vitro cell 
culture assays over this time period as assessed by the ability to block TGF-mediated induction of 
SMAD2 phosphorylation (Fig. 3C). AZ12601011 and AZ12799734 can therefore be used to effectively 
block TGFβ signalling in phenotypic assays over a 10 day time course.  
Previous drugs designed to target the TGF type 1 receptor, such as SB-431542, effectively inhibit the 
activity of activin and nodal receptors ALK4 and ALK7 in addition to TGFBR1. Using transient 
transfection assays, we therefore also assessed the effect of AZ12601011 and AZ12799734 on 
constitutively active ALK4, ALK7 and TGFBR1 receptors expressed in NIH3T3 CAGA12 reporter 
cells. Induction of CAGA12-luciferase reporter activity induced by transient transfection of the 
constitutively active receptors is shown in Fig. 4A. Following transient transfection, cells were treated 
with a titration of AZ12601011 and AZ12799734 and the effect on CAGA12 reporter activity monitored 
(Fig. 4B).  AZ12601011 inhibited the activity of ALK4, ALK7 and TGFBR1 at concentrations between 
0.01µM – 10M equally. AZ12799734 also inhibited the three constitutively active receptors equally 
at concentrations ranging from 1M – 10M. We next tested the effect of AZ12601011 and 
AZ12799734 on receptor regulated SMAD phosphorylation by transient transfection of constitutively 
active receptors into NIH3T3 cells (Fig. 4C). Phosphorylation of co-transfected SMAD1 and SMAD2 
by the active receptors was monitored by western blot.  All seven receptors induced phosphorylation of 
either SMAD1 or SMAD2; as expected, phosphorylation of SMAD1 occurred following transfection 
of ALK1, BMPR1A and BMPR1B, and phosphorylation of SMAD2 occurred following transfection of 
ALK4, TGFBR1 and ALK7 (Fig. 4C).  AZ12601011 inhibited phosphorylation of SMAD2 but not 
SMAD1, suggesting that (like SB-431542) AZ12601011 is a selective inhibitor of ALK4, TGFBR1 and 
ALK7.  
AZ12799734, however, inhibited phosphorylation of both SMAD1 and SMAD2 and is thus likely to be 
a pan BMP/TGF receptor inhibitor. The effect of AZ12999734 on BMP signalling was confirmed using 
a bioassay measuring the transcriptional activation of a BMP responsive element luciferase reporter 
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construct (C2C12-BRE-LUC) (Herrera and Inman, 2009) after exogenous addition of BMP4, BMP6 or 
GDF2 (BMP9). As expected, given that there was no effect of AZ12601011 on SMAD1 
phosphorylation, we saw no inhibition of BMP-induced activity of C2C12-BRE-LUC in AZ12601011 
treated cells (Fig. 5A). Following treatment by AZ12601011, we observed no inhibition of extracellular 
signals regulating phosphorylation of ERK (induced by EGF) (Fig5B) or p38 MAPK family members 
(induced by osmotic shock) (Fig. 5C). AZ12601011 therefore had no inhibitory off-target effect on the 
EGF-activated EGFR/MEK/ERK signalling cascade (Bogdan and Klambt, 2001) which was efficiently 
blocked by the MEK1/2 inhibitor, U0126, which was used as a positive control for MEK1/2 inhibition 
(Fig. 5B).   
 
AZ12601011 and AZ12999734 inhibit TGF-induced migration.   
AZ12601011 and AZ12799734 were assessed in functional wound healing assays using HaCaT 
epithelial cells that measure a TGF-inducible SMAD4-dependent migration responses (Levy and Hill, 
2005). Confluent monolayers of serum-starved (0.2% FBS) HaCaT cells were uniformly scratched 
using a Woundmaker (Essen Biosciences), and the resulting wound closure was analysed by real time 
imaging (Fig. 6).  Serum starved DMSO control treated cells migrated to close the wound by just over 
80% after 80 hours incubation. Following treatment with TGF, however, HaCaT cells migrated faster 
to close the wound entirely within 36 hours. When cells were pre-treated with different concentrations 
of SB-431542, galunisertib, AZ12601011 or AZ12799734 prior to TGF addition, we observed dose-
dependent decreases in TGFβ-induced migration. SB-431542, galunisertib, AZ12601011 and 
AZ12799734 blocked the increase in migration at concentrations of 500nM, 5000nM, 100nM and 
500nM, respectively.  At 500nM, AZ12601011 reduced cell migration below baseline, which was only 
achieved at doses ≥5M of SB-431542 and AZ12799734 (data not shown).  AZ12601011 therefore was 
the most effective inhibitor in the wound healing assay, which inhibited TGF-induced migration at 
concentrations at least 10-fold lower than galunisertib.  
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AZ12601011 inhibits tumour growth and metastasis in vivo. 
The selectivity profile of AZ12601011 for ALK4, ALK5 and ALK7 (similar in scope to galunisertib in 
clinical trials) made it a good representative probe molecule to understand the profile of a TGFBR1 
inhibitor in vivo, We tested the pharmacokinetics of both drugs (total and free) in BALB/c mice 
following administration of 50mg/kg dose (Fig. 7A), and tested the effect of AZ12601011 on 4T1 cell 
proliferation in vitro prior to its use in an in vivo assay of preventative treatment of 4T1 syngeneic 
orthotopic tumour growth. AZ12601011 inhibited 4T1 proliferation with an IC50 of 400nM (Figure 7B). 
In the orthotopic in vivo assay, AZ12601011 inhibited signalling measured by a reduction in detection 
of phosphorylated SMAD2 in tumour cell lysates 1 hour after administration (50mg/kg) (Fig.7C).  
AZ12601011 inhibited 4T1 cells growth in vitro (IC50 = 0.4µM) (Fig.7C). To assess efficacy in vivo, 
mice were treated twice daily with vehicle or AZ12601011 (50mg/kg) starting the day after implant of 
4T1 cells into mammary fat pads. Tumour growth was monitored over 25 days (Fig. 7D). The average 
tumour size in the treated (n=10) group up to day 18 (when 13/13 mice in the control group remained 
in the study) was significantly inhibited by AZ12601011 (p=0.0001) compared to controls (n=13) (Fig. 
7E). 2/13 mice in the control group had to be sacrificed before the end of the study at days 18 and 23 
due to large tumour sizes. No tumours in the treated group exceeded the stipulated size limit and 1/10 
mice did not develop a measurable tumour. We noted a significant increase in event-free survival 
(p=0.002) and in the time taken to develop tumours exceeding 0.5cm3 (p<0.005) in the treated mice 
(Fig. 7F).   Importantly, we also found a statistically significant reduction (p = 0.025) in the median 
lung metastasis score in mice treated with AZ12601011 (median = 1) compared to the control group 
(median = 4), U = 26, z = -2.267, using an exact sampling distribution for U. 
AZ12601011 therefore shows efficacy as a single agent therapy in tumour model systems providing a 
TGFBR1 inhibitor lead compound for future development.    
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DISCUSSION 
Our data describe the specificity and efficacy of two compounds designed to inhibit TGFBR1 kinase 
activity (AZ12601011 and AZ12799734) in a number of cell-based assays. We provide evidence that 
AZ12601011 targets ALK4 and ALK7 as well as TGFBR1, while AZ12799734 is a pan inhibitor of 
ALK1, ALK2, BMPR1A, ALK4, TGFBR1, BMPR1B and ALK7. Thus, although not directly tested 
here, we predict that like SB-431542, AZ12601011 will also inhibit activin and nodal signalling through 
ALK4 and ALK7. AZ127994734, we anticipate, may be useful as a single agent combined inhibitor of 
TGF and BMP activity.  
The efficacy of AZ12601011 and AZ12799734 was also assessed in biological assays of TGF-induced 
transcription and migration. TGF-induced migration of HaCaT epithelial cells is, in part, reported to 
involve TGF-mediated activation of a genetic program regulated by the ERK signalling pathway 
demonstrated by the observation that the MEK/ERK inhibitor U2016 can inhibit this response (Zavadil 
et al., 2001). Since 100nM concentrations of AZ12601011 inhibited migration but had no effect on 
EGF-induced phosphorylation of ERK or p38 phosphorylation up to concentrations of 10M, we 
conclude that the effects of the inhibitors on migration are not a result of off target inhibition of 
MEK/ERK but are likely a result of on-target TGFBR1 inhibition. In these assays, AZ12601011 and 
AZ12799734 were at least 10-fold more effective in blocking TGF-induced transcription and 
migration than galunisertib currently in clinical trials. Importantly, AZ12601011 reduced signalling via 
SMAD2 in vivo and also inhibited tumour growth and metastasis of in an orthotopic murine model of 
breast cancer, suggesting therapeutic potential.  
The development of novel inhibitors of TGFBR1 could provide new therapeutic options in TGF-
associated pathologies such as cancer and fibrosis. The clinical use of TGFBR1 inhibitors, however, is 
not without concerns over patient safety. TGF signalling via TGFBR1 has a role in cardiac 
development (Sridurongrit et al., 2008) and several heart defects are evident in TGF2 null mice. 
Because increased TGF expression is involved in cardiac remodelling in response to numerous stresses 
(Lim and Zhu, 2006), TGFBR1 inhibitors are predicted to be of benefit in combating the effects of 
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cardiac remodelling in heart failure. However, administration of AZ12601011 to disease-free wild type 
mice is associated with cardiac toxicity involving the development of aortic lesions (Anderton et al., 
2011). Questions over these homeostatic functions of TGF have thus delayed development of lead 
compounds like LY2157299 (galunisertib). Similar effects of galunisertib on small mammals were 
noted during detailed pre-clinical toxicity testing, but, were ameliorated by lower doses and careful 
dosing schedules (Herbertz et al., 2015). These concerns therefore appear to be largely overcome and 
several cancer related trials of galunisertib as a monotherapy, or in combination with other 
chemotherapeutics, are ongoing. The efficacy of galunisertib in models of cancer, however, appears 
limited by tumour environmental factors and anti-tumour growth inhibitory effects are lacking in some 
xenograft models (Herbertz et al., 2015; Maier et al., 2015). In hepatocellular cancer cells, galunisertib 
had minimal effects on proliferation, but inhibited invasion (Serova et al., 2015). Most of the studies to 
date have focussed on anti-proliferative and tumour-killing potential in standard assays, and there is 
growing evidence that these inhibitors may be more effective in cancer models measuring metastasis, 
immune function and cancer stem cell-like properties (Anido et al., 2010; Maurantonio et al., 2011; 
Penuelas et al., 2009; Spender et al., 2016). For example, galunisertib has been shown to inhibit TGFβ 
induced migration and immune suppression in vitro (Yingling et al., 2018).  In addition, SB-431542 
inhibits mutant BRAF melanoma cell migration and stem-cell like properties of anchorage independent 
growth and clonogenicity at low-cell density. These effects are overcome by increasing cell density 
leading to the conclusion that the dependence of tumour cells on TGF/TGFBR1 signalling is revealed 
under conditions of cellular stress. TGFBR1 inhibitors may therefore be most effective in inhibiting 
micrometastasis seeding or outgrowth, following removal of any clinically apparent tumour mass 
(Spender et al., 2016). This conclusion is supported by the inhibitory effect of AZ12601011 on HaCaT 
cell migration and the formation of 4T1 lung metastasis in our experimental cell based assays. Hence, 
TGF receptor inhibitors remain candidate therapeutic agents with therapeutic potential, despite the 
lack of significant tumour killing by galunisertib. Additionally, galunisertib has shown promise in ex 
vivo models of fibrotic disease (Luangmonkong et al., 2017). AZ12601011 and AZ12799734 therefore 
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provide new tools for studying TGF and BMP regulated biological processes and lead compounds for 
clinical development.    
  
This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on November 20, 2018 as DOI: 10.1124/mol.118.112946
 at A
SPET Journals on N
ovem
ber 28, 2018
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
MOL#112946 
 
21 
 
 
ACKNOWLEDGEMENTS 
 
The authors would like to express their gratitude to the following people who provided valuable 
assistance: In vivo tissue culture support was provided by Suzanne Meredith. DMPK method and data 
support was provided by Rebecca Broadhurst and Joanne Wilson. Pharmacodynamic methodology and 
data support provided by Michelle Scott and Adina Hughes.  
 
 
AUTHORSHIP CONTRIBUTIONS  
Participated in research design: Spender, Sansom, Hughes, Goldberg, Davies, Barry, Herrera, Ferguson 
and Inman. 
Conducted experiments: Spender, Ferguson, Taylor, Strathearn, Herrera, Barry, Hughes, Goldberg, 
Davies and Inman. 
Performed data analysis: Spender, Herrera, Ferguson, Taylor, Hughes, Davies, Barry and Inman. 
Wrote or contributed to the writing of the manuscript: Spender, Barry, Taylor, Herrera, Sansom, 
Goldberg, Davies, Hughes and Inman. 
Davies, Hughes, Goldberg and Barry are employees and shareholders of AstraZeneca. Ferguson is an 
employee of an AstraZeneca owned company and is a shareholder of AstraZeneca.  
  
This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on November 20, 2018 as DOI: 10.1124/mol.118.112946
 at A
SPET Journals on N
ovem
ber 28, 2018
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
MOL#112946 
 
22 
 
REFERENCES 
Akhurst, R.J., and Hata, A. (2012). Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug 
Discov 11, 790‐811. 
 
Anderton, M.J., Mellor, H.R., Bell, A., Sadler, C., Pass, M., Powell, S., Steele, S.J., Roberts, R.R., and 
Heier, A. (2011). Induction of heart valve lesions by small‐molecule ALK5 inhibitors. Toxicol Pathol 39, 
916‐924. 
 
Anido, J., Saez‐Borderias, A., Gonzalez‐Junca, A., Rodon, L., Folch, G., Carmona, M.A., Prieto‐Sanchez, 
R.M., Barba, I., Martinez‐Saez, E., Prudkin, L., et al. (2010). TGF‐beta Receptor Inhibitors Target the 
CD44(high)/Id1(high) Glioma‐Initiating Cell Population in Human Glioblastoma. Cancer Cell 18, 655‐
668. 
 
Blobe, G.C.,  Schiemann, W.P.,  and  Lodish, H.F.  (2000).  Role of  transforming  growth  factor beta  in 
human disease. N Engl J Med 342, 1350‐1358. 
 
Bogdan, S., and Klambt, C. (2001). Epidermal growth factor receptor signaling. Curr Biol 11, R292‐295. 
Davis, R.J. (2000). Signal transduction by the JNK group of MAP kinases. Cell 103, 239‐252. 
 
Dennler,  S.,  Itoh, S., Vivien, D.,  ten Dijke, P., Huet,  S.,  and Gauthier,  J.M.  (1998). Direct binding of 
Smad3 and Smad4 to critical TGF beta‐inducible elements  in  the promoter of human plasminogen 
activator inhibitor‐type 1 gene. Embo J 17, 3091‐3100. 
 
Fujiwara, Y., Nokihara, H., Yamada, Y., Yamamoto, N., Sunami, K., Utsumi, H., Asou, H., Takahash, I.O., 
Ogasawara, K., Gueorguieva, I., et al. (2015). Phase 1 study of galunisertib, a TGF‐beta receptor I kinase 
inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 76, 1143‐
1152. 
 
Gellibert, F., de Gouville, A.C., Woolven, J., Mathews, N., Nguyen, V.L., Bertho‐Ruault, C., Patikis, A., 
Grygielko,  E.T.,  Laping,  N.J.,  and  Huet,  S.  (2006).  Discovery  of  4‐{4‐[3‐(pyridin‐2‐yl)‐1H‐pyrazol‐4‐
yl]pyridin‐2‐yl}‐N‐(tetrahydro‐2H‐ pyran‐4‐yl)benzamide (GW788388): a potent, selective, and orally 
active transforming growth factor‐beta type I receptor inhibitor. J Med Chem 49, 2210‐2221. 
 
Goldberg, F.W., Ward, R.A., Powell, S.J., Debreczeni, J.E., Norman, R.A., Roberts, N.J., Dishington, A.P., 
Gingell,  H.J.,  Wickson,  K.F.,  and  Roberts,  A.L.  (2009).  Rapid  generation  of  a  high  quality  lead  for 
transforming growth factor‐beta (TGF‐beta) type I receptor (ALK5). J Med Chem 52, 7901‐7905. 
 
Herbertz,  S.,  Sawyer,  J.S.,  Stauber,  A.J.,  Gueorguieva,  I.,  Driscoll,  K.E.,  Estrem,  S.T.,  Cleverly,  A.L., 
Desaiah, D., Guba, S.C., Benhadji, K.A., et al. (2015). Clinical development of galunisertib (LY2157299 
monohydrate), a small molecule inhibitor of transforming growth factor‐beta signaling pathway. Drug 
Des Devel Ther 9, 4479‐4499. 
 
Herrera, B., and Inman, G.J. (2009). A rapid and sensitive bioassay for the simultaneous measurement 
of multiple bone morphogenetic proteins. Identification and quantification of BMP4, BMP6 and BMP9 
in bovine and human serum. BMC Cell Biol 10, 20. 
 
Inman, G.J. (2011). Switching TGFbeta from a tumor suppressor to a tumor promoter. Current opinion 
in genetics & development 21, 93‐99. 
 
This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on November 20, 2018 as DOI: 10.1124/mol.118.112946
 at A
SPET Journals on N
ovem
ber 28, 2018
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
MOL#112946 
 
23 
 
Inman, G.J., Nicolas, F.J., Callahan, J.F., Harling, J.D., Gaster, L.M., Reith, A.D., Laping, N.J., and Hill, C.S. 
(2002). SB‐431542 is a potent and specific inhibitor of transforming growth factor‐beta superfamily 
type I activin receptor‐like kinase (ALK) receptors ALK4, ALK5, and ALK7. Molecular pharmacology 62, 
65‐74. 
 
Kovacs,  R.J.,  Maldonado,  G.,  Azaro,  A.,  Fernandez,  M.S.,  Romero,  F.L.,  Sepulveda‐Sanchez,  J.M., 
Corretti,  M.,  Carducci,  M.,  Dolan,  M.,  Gueorguieva,  I.,  et  al.  (2015).  Cardiac  Safety  of  TGF‐beta 
Receptor  I  Kinase  Inhibitor  LY2157299 Monohydrate  in  Cancer  Patients  in  a  First‐in‐Human  Dose 
Study. Cardiovasc Toxicol 15, 309‐323. 
 
Lahn, M., Kloeker, S., and Berry, B.S. (2005). TGF‐beta inhibitors for the treatment of cancer. Expert 
Opin Investig Drugs 14, 629‐643. 
 
Levy, L., and Hill, C.S. (2005). Smad4 dependency defines two classes of transforming growth factor 
{beta}  (TGF‐{beta})  target  genes  and  distinguishes  TGF‐{beta}‐induced  epithelial‐mesenchymal 
transition from its antiproliferative and migratory responses. Mol Cell Biol 25, 8108‐8125. 
 
Lim, H.,  and  Zhu,  Y.Z.  (2006).  Role of  transforming  growth  factor‐beta  in  the progression of  heart 
failure. Cell Mol Life Sci 63, 2584‐2596. 
 
Luangmonkong, T., Suriguga, S., Bigaeva, E., Boersema, M., Oosterhuis, D., de Jong, K.P., Schuppan, 
D., Mutsaers, H.A.M., and Olinga, P.  (2017). Evaluating the antifibrotic potency of galunisertib  in a 
human ex vivo model of liver fibrosis. British journal of pharmacology 174, 3107‐3117. 
 
Maier,  A.,  Peille,  A.L.,  Vuaroqueaux,  V.,  and  Lahn, M.  (2015).  Anti‐tumor  activity  of  the  TGF‐beta 
receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient‐derived tumor xenografts. 
Cell Oncol (Dordr) 38, 131‐144. 
 
Maurantonio,  M.,  Ballestri,  S.,  Odoardi,  M.R.,  Lonardo,  A.,  and  Loria,  P.  (2011).  Treatment  of 
atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to 
reduce cardiovascular risk? Archives of medical research 42, 337‐353. 
 
Park,  J.H.,  Ryu,  S.H.,  Choi,  E.K.,  Ahn,  S.D.,  Park,  E.,  Choi,  K.C.,  and  Lee,  S.W.  (2015a).  SKI2162,  an 
inhibitor of the TGF‐beta type I receptor (ALK5), inhibits radiation‐induced fibrosis in mice. Oncotarget 
6, 4171‐4179. 
 
Park, S.A., Kim, M.J., Park, S.Y., Kim,  J.S., Lee, S.J., Woo, H.A., Kim, D.K., Nam, J.S., and Sheen, Y.Y. 
(2015b). EW‐7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF‐beta/Smad and ROS 
signaling. Cell Mol Life Sci 72, 2023‐2039. 
 
Penuelas, S., Anido, J., Prieto‐Sanchez, R.M., Folch, G., Barba, I., Cuartas, I., Garcia‐Dorado, D., Poca, 
M.A.,  Sahuquillo,  J., Baselga,  J.,  et al.  (2009).  TGF‐beta  increases glioma‐initiating  cell  self‐renewal 
through the induction of LIF in human glioblastoma. Cancer Cell 15, 315‐327. 
 
Ramachandran, A., Vizan, P., Das, D., Chakravarty, P., Vogt, J., Rogers, K.W., Muller, P., Hinck, A.P., 
Sapkota,  G.P.,  and  Hill,  C.S.  (2018).  TGF‐beta  uses  a  novel  mode  of  receptor  activation  to 
phosphorylate SMAD1/5 and induce epithelial‐to‐mesenchymal transition. eLife 7. 
 
Schmierer,  B.,  and  Hill,  C.S.  (2007).  TGFbeta‐SMAD  signal  transduction:  molecular  specificity  and 
functional flexibility. Nat Rev Mol Cell Biol 8, 970‐982. 
 
This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on November 20, 2018 as DOI: 10.1124/mol.118.112946
 at A
SPET Journals on N
ovem
ber 28, 2018
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
MOL#112946 
 
24 
 
Serova, M., Tijeras‐Raballand, A., Dos Santos, C., Albuquerque, M., Paradis, V., Neuzillet, C., Benhadji, 
K.A., Raymond, E., Faivre, S., and de Gramont, A. (2015). Effects of TGF‐beta signalling inhibition with 
galunisertib  (LY2157299)  in  hepatocellular  carcinoma  models  and  in  ex  vivo  whole  tumor  tissue 
samples from patients. Oncotarget 6, 21614‐21627. 
 
Shi, Y., and Massague, J. (2003). Mechanisms of TGF‐beta signaling from cell membrane to the nucleus. 
Cell 113, 685‐700. 
 
Spender, L.C., Ferguson, G.J., Liu, S., Cui, C., Girotti, M.R., Sibbet, G., Higgs, E.B., Shuttleworth, M.K., 
Hamilton,  T.,  Lorigan,  P.,  et  al.  (2016).  Mutational  activation  of  BRAF  confers  sensitivity  to 
transforming growth factor beta inhibitors in human cancer cells. Oncotarget 7, 81995‐82012. 
 
Sridurongrit, S., Larsson, J., Schwartz, R., Ruiz‐Lozano, P., and Kaartinen, V. (2008). Signaling via the 
Tgf‐beta type I receptor Alk5 in heart development. Dev Biol 322, 208‐218. 
 
Vogt,  J., Traynor, R., and Sapkota, G.P.  (2011). The  specificities of  small molecule  inhibitors of  the 
TGFss and BMP pathways. Cell Signal 23, 1831‐1842. 
 
Wang, R.N., Green, J., Wang, Z., Deng, Y., Qiao, M., Peabody, M., Zhang, Q., Ye, J., Yan, Z., Denduluri, 
S., et al. (2014). Bone Morphogenetic Protein (BMP) signaling in development and human diseases. 
Genes Dis 1, 87‐105. 
 
Yingling,  J.M., McMillen, W.T.,  Yan,  L.,  Huang,  H.,  Sawyer,  J.S.,  Graff,  J.,  Clawson,  D.K.,  Britt,  K.S., 
Anderson,  B.D.,  Beight,  D.W.,  et  al.  (2018).  Preclinical  assessment  of  galunisertib  (LY2157299 
monohydrate), a first‐in‐class transforming growth factor‐beta receptor type I inhibitor. Oncotarget 9, 
6659‐6677. 
 
Zavadil, J., Bitzer, M., Liang, D., Yang, Y.C., Massimi, A., Kneitz, S., Piek, E., and Bottinger, E.P. (2001). 
Genetic programs of epithelial cell plasticity directed by transforming growth factor‐beta. Proc Natl 
Acad Sci U S A 98, 6686‐6691. 
 
Zhang, Y.E. (2009). Non‐Smad pathways in TGF‐beta signaling. Cell Res 19, 128‐139. 
 
  
This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on November 20, 2018 as DOI: 10.1124/mol.118.112946
 at A
SPET Journals on N
ovem
ber 28, 2018
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
MOL#112946 
 
25 
 
 
FOOTNOTES 
Davies, Hughes, Goldberg and Barry are employees and shareholders of AstraZeneca. This work was 
partially funded by AstraZeneca. Spender, Inman, Ferguson and Herrera were supported by Cancer 
Research UK and Worldwide Cancer Research (International Fellowship to GJI and 11-0788).  
This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on November 20, 2018 as DOI: 10.1124/mol.118.112946
 at A
SPET Journals on N
ovem
ber 28, 2018
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
MOL#112946 
 
26 
 
 
FIGURE LEGENDS 
Figure 1. Activity of five TGFBR1 inhibitors in TGFβ-induced SMAD3/4 dependent reporter 
assays.  (A). Chemical structures of AZ12601011 (previously undisclosed) and AZ12799734 (Goldberg 
et al., 2009). (B) TGFβ-inducible SMAD3/4 dependent CAGA12 promoter-luciferase reporter bioassay 
carried out both in the absence (-) and presence (+) of exogenous addition of TGFβ1 (1ng/mL) for 8 
hours. Stably transfected NIH 3T3 CAGA12 cells were pre-treated with a titration of SB-431542, SB-
525334, AZ12601011, AZ12799734 or LY2157299 for 15 minutes prior to induction of luciferase 
activity by exogenous TGFβ addition. The mean (± S.D.) activity (as a % of the control cells + TGF) 
is shown from a representative experiment. (C) Representative dose response curves of TGFBR1 
inhibitors generated from CAGA12 bioassays as shown in (B). Data is presented as a percentage of 
luciferase activity of untreated control cells + TGFβ (100%). (D) Mean ± s.d.  IC50 determined by 
median effect plots using CalcuSyn curve fit software and IC50 and 95% confidence intervals 
determined by non-linear regression analysis using Graphpad Prism 7 software are shown. The IC50s 
were generated from replicate independent dose response curves AZ12601011 (n=4), AZ12799734 
(n=3), SB-525334 (n=4), SB-431542 (n=5), LY2157299 (n=4).  
 
Figure 2. Inhibition of TGFβ-induced phosphorylation of SMAD2 by AZ12601011. (A) 
Representative SDS-PAGE and western blot analysis for phosphorylated SMAD2 and total SMAD2 of 
RIPA lysates from two independent experiments where cell lines pre-treated with a titration of 
AZ12601011 for 20 minutes followed by exogenous addition of TGF (5ng/mL) for 1 hour. (B-D) LI-
COR odyssey infrared imaging quantification of phospho-SMAD2 (ser465/467) normalised to pan-
SMAD2 levels in HaCaT cells pre-treated with a titration of AZ12601011 (range 10µM – 0.01µM) 
prior to TGFβ addition for 1 hour (n=3). Representative scanned blots (B) and combined raw intensity 
signals from infrared imaging of pan-SMAD2 and phospho-SMAD2 western blots - lane 2 (untreated 
+ TGFβ) (C). (D) Bar chart depicting the mean ± s.e.m (n=3) ratio of phospho-SMAD2 normalised 
signal intensity relative to the untreated control (lane1) from replicate assays.  
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Figure 3. Assessment of TGFBR1 inhibitors in in vitro culture systems. (A) NIH3T3 CAGA12-
luciferase cells were left untreated or pre-treated for 15 minutes with 20nM AZ12601011 and 60nM 
AZ12799734 that had undergone the indicated number of freeze thaw cycles. Following pre-treatment, 
the reporter cells were stimulated with 1ng/mL TGF for 8 hours, lysed and the relative luciferase units 
(RLU) measured. Results are presented as the mean RLU (± S.D.) normalised to protein content of the 
lysate of three replicate wells. (B) Cell culture media (DMEM + 10% FBS) was spiked with 10µM 
inhibitors and incubated at 37ºC for the times indicated. On Day 9, HaCaT cells were seeded at 
overnight at 5x104 in 24-well plates. Media was removed from the wells and replaced with inhibitor 
spiked media for 15 minutes pre-treatment prior to addition of TGF-β at 5ng/mL for 2 hours. Cell lysates 
were analysed by SDS-PAGE and western blot for phosphorylated SMAD2 and -Actin as a loading 
control (n=1). (C) 1x106 VU-SCC-040 cells were seeded overnight into 10cm dishes and treated with 
solvent control (DMSO), SB-431542, Galunisertib, AZA12601011 or AZ12799734 at 10µM final 
concentration. Treated cells were incubated for the times shown and then challenged with exogenous 
TGFβ1 (5ng/mL) for 2 hours. Cell lysates were analysed by SDS-PAGE and western blot for 
phosphorylated SMAD2 and -Actin as a loading control. Representative western blots from replicate 
biological experiments (n=2) showing similar results are shown. 
 
Figure 4. Selectivity of AZ12601011 and AZ12799734 against TGFβ superfamily type 1 
receptors.(A, B) 4.5 x 104 NIH3T3 cells were seeded in 24-well plates and incubated overnight. Cells 
were transfected with 100ng CAGA12-luciferase reporter and 150ng plasmids expressing constitutively 
active (*) type 1 receptors ALK4, TGFBR1 or ALK7. After 24 hours the relative luciferase activity was 
measured in cell lysates. RLUs were normalised to protein content and expressed as the mean RLU (± 
S.D.) from a minimum of 3 replicate wells. (B) Cells were transfected as described in (A) and treated 
with a titration of either AZ12601011 or AZ12799734 as indicated. Results are shown as the mean 
percent RLU (± S.D.) relative to control samples.  (C)  NIH3T3 cells were co-transfected in singlicate 
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with 500ng SMAD1 or SMAD2 expression plasmids and 500ng plasmids expressing constitutively 
active (*) receptors. Cells were either left untreated or treated with 10M AZ12601011 or AZ12799734 
for 24 hours prior to lysis and analysis of lysates by SDS-PAGE and western blotting for the proteins 
indicated.   
 
Figure 5. Selectivity of AZ12601011 and AZ12799734 in cell based assays. (A) C2C12-BRE-
LUC cells were pre-treated with a titration of AZ12601011 and AZ12799734 for 20 minutes prior to 
addition of 5ng/mL recombinant BMP ligand. Luciferase activity was measured using the Luciferase 
assay system (Promega). Results presented are the mean fold activation of the luciferase reporter in 
response to ligand relative to activity in untreated cells. (B, C) Serum starved (0.1% FBS) NIH3T3 cells 
were pre-treated in singlicate with a titration of AZ12601011 (as indicated) for 20 minutes prior to 
stimulation for 5 minutes with EGF (30ng/mL) (B) or osmotic shock treatment for 20 minutes with 
NaCl (0.7M) (C). U0126 treatment at 25M was included as a positive control for inhibition of EGF 
signalling via the MAPK pathway (B). Cells were then washed in ice cold PBS and lysed in RIPA. 
Protein lysates were quantified and equal amounts of protein analysed by SDS-PAGE and western blots 
for the proteins indicated are shown.   
 
Figure 6: Blockade of TGFβ-induced migration. HaCaT cells were seeded at 15,000 cells/well in 
ImageLock plates (Essen Biosciences) and incubated overnight. Cells were washed twice in PBS and 
serum starved for 24 hours in DMEM supplemented with 0.2% FBS. Uniform wounds were generated 
using a Woundmaker, the cells washed twice in PBS, and then pre-treated with titrations of SB-431542, 
AZ12601011 or AZ12799734 in DMEM/0.2% FBS followed by BSA/HCL carrier control or TGF 
(5ng/mL). Closure of the wound was monitored by IncuCyte Zoom imaging over 4 days. Data presented 
is the mean ± S.E.M of a minimum of three replicate wells taken from a representative experiment.   
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Figure 7: In vivo profile of TGFBR1 inhibitors. (A) Total and free PK levels of AZ12601011 and 
AZ12799734 in the nude mouse following 50mg/kg per oral dose, with time over in vitro IC50 
(0.01582μM and 0.01885μM respectively). (B) Growth of 4T1 cells (shown as a percentage of vehicle 
treated control cells) treated with AZ12601011. Growth was determined after 4 days treatment using 
the IncucyteZoom real time imaging system. (C) PD modulation of pSMAD2 levels following treatment 
for with AZ12601011 (50mg/kg BID) in the mouse 4T1 syngeneic cell line grown via mammary 
orthotopic implant. pSMAD2 levels were measured in tumour cell lysates by ELISA 1hour after drug 
administration. (D) Mouse 4T1 syngeneic orthotopic tumour growth over 25 days in vehicle control 
(n=13) and AZ12601011 (50mg/kg BID) (n=10) treated mice. Mice were treated by oral gavage twice 
daily from day 1 following implant. Tumour volumes in individual mice are shown.  (E) Mean ± SEM 
tumour volumes of all mice in the vehicle control and AZ12601011 treated groups until day of first 
sacrifice (Day 18). Statistical analysis was carried out by pairwise comparison using the 
compareGrowthCurves function in statmod (R project). The adjusted p value is shown. (F) Kaplan-
meier plots showing statistically significant differences in event-free (left) [Log Rank (Mantel-Cox) 
χ2(1) = 9.191, p < .002] and tumour <0.5cm3 (right) [Log Rank (Mantel-Cox) χ2(1) = 17.448, p = 
0.00003] survival. (Control group n=13; Treated group n=10). (G) Scatterplot showing relative lung 
metastasis scores in the 4T1 syngeneic orthotopic tumour mice (described in D to F) following vehicle 
control (n=12) or AZ12601011 treatment (n=10). The scatterplot points represent individual mice, and 
bars represent the median and the interquartile ranges. Analysis was carried out using Mann-Whitney 
U test. AZ12601011 treated group (median = 1); vehicle control group (median = 4), U = 26, z = -2.267, 
p = .025, using an exact sampling distribution for U. 
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